compar effect apsac rt-pa infarct size ventricular function acut myocardi infarct multicent studi background recombin tissue-typ plasminogen activ rt-pa alteplas plasminogen streptokinas activ complex apsac anistreplas infarct size left ventricular function acut myocardi infarct efficaci safeti thrombolyt agent trial aim studi method result eighty-thre patient first acut myocardi infarct apsac unit minut single-chain rt-pa mg period hour onset symptom global region left ventricular function contrast angiographi averag day initi therapi radionuclid angiographi single-photon emiss tomographi hospit discharg infarct size single-photon emiss tomographi percentag total myocardi volum nineti patient apsac rt-pa mean period minut onset symptom group similar age locat acut myocardi infarct killip class time random patenc rate infarct-rel arteri apsac group rt-pa group NS initi predischarg ventricular eject fraction infarct size similar therapeut group versu initi versu predischarg eject fraction versu infarct size apsac- rt-pa-treat patient complic blood transfus apsac patient rt-pa patient patient rt-pa group massiv intracrani hemorrhag end follow-up period apsac patient rt-pa patient conclus earli infus apsac rt-pa acut myocardi infarct similar patenc rate limit infarct size preserv left ventricular systol function equival rate complic 